Literature DB >> 1688848

Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor.

J W Smith1, D A Cheresh.   

Abstract

The vitronectin receptor mediates cell adhesion to the extracellular matrix proteins vitronectin, fibrinogen, von Willebrand factor, and thrombospondin in an RGD-dependent manner. We previously demonstrated the direct interaction between the vitronectin receptor and an RGD-containing peptide by photoaffinity labeling the receptor with 125I-sulfosuccinimidyl-2-(p-azido-salicylamido)-1,3'-dithioprop ion ate (SASD)-GRGDSPK (Smith, J. W., and Cheresh, D. A. (1988) J. Biol. Chem. 263, 18726-18731). In that report, we identified amino acid residues 61-203 of the beta-subunit as proximal to the ligand binding site. Here we demonstrate that 125I-SASD-GRGDSPK affinity labels the alpha-subunit of the receptor at least two distinct sites within the region encompassing residues 139-349. Both of these regions are within the putative divalent cation binding region of the alpha-subunit. Collectively, our results suggest that discrete amino-terminal domains of both subunits of the receptor contribute to the structure of the ligand binding domain and furthermore that the ligand and divalent cation binding domains are spatially and functionally linked.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688848

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain.

Authors:  L A Bunce; L A Sporn; C W Francis
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

Review 2.  Extracellular matrix molecules and their receptors: functions in neural development.

Authors:  L F Reichardt; K J Tomaselli
Journal:  Annu Rev Neurosci       Date:  1991       Impact factor: 12.449

3.  Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression.

Authors:  Markus Waldeck-Weiermair; Cristina Zoratti; Wolfgang F Graier; Karin Osibow; Nariman Balenga; Edith Goessnitzer; Maria Waldhoer; Roland Malli
Journal:  J Cell Sci       Date:  2008-04-29       Impact factor: 5.285

4.  The integrin VLA-2 binds echovirus 1 and extracellular matrix ligands by different mechanisms.

Authors:  J M Bergelson; B M Chan; R W Finberg; M E Hemler
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

5.  Modeling the alpha IIb beta 3 integrin solution conformation.

Authors:  M Rocco; B Spotorno; R R Hantgan
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

6.  Defining extracellular integrin alpha-chain sites that affect cell adhesion and adhesion strengthening without altering soluble ligand binding.

Authors:  C Pujades; R Alon; R L Yauch; A Masumoto; L C Burkly; C Chen; T A Springer; R R Lobb; M E Hemler
Journal:  Mol Biol Cell       Date:  1997-12       Impact factor: 4.138

7.  Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain.

Authors:  T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

8.  Regulation of integrin function: evidence that bivalent-cation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin alpha5 beta1.

Authors:  A P Mould; A N Garratt; W Puzon-McLaughlin; Y Takada; M J Humphries
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

9.  Thrombospondin-1 binds to polyhistidine with high affinity and specificity.

Authors:  V K Vanguri; S Wang; S Godyna; S Ranganathan; G Liau
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

10.  Characterization of integrin engagement during defined human embryonic stem cell culture.

Authors:  Ying Meng; Shawdee Eshghi; Ying J Li; Ray Schmidt; David V Schaffer; Kevin E Healy
Journal:  FASEB J       Date:  2009-11-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.